RT @synovialjoints@twitter.com
My journey on Rheum Twitter #rheumedu began at the #ACR13 Tweet Up where I made a long lasting friendship with Phil @philipcrobinson@twitter.com he was always smiling, encouraging and called me mate. We discussed and caught up at meetings. We will always very fond memories of our dear friend
🐦🔗: https://twitter.com/synovialjoints/status/1611694790965448706
MTX is the cornerstone therapy for so much of Rheumatology. I can't imagine being a rheumatologist without it.
RT @RheumTweeter@twitter.com
This thread is a condensation of the great article by Dr Michael E. Weinblatt, who played a pivotal role in the implementation of #MTX
It'a a great read, and I can highly recommend it! http://bit.ly/3F1gsJZ
10/🧵 #RheumEdu #RheumTwitter #MedTwitter
🐦🔗: https://twitter.com/RheumTweeter/status/1598837992420167680
#MTX #rheumedu #RheumTwitter #medtwitter
This thread is a condensation of the great article by Dr Michael E. Weinblatt, who played a pivotal role in the implementation of #MTX
It'a a great read, and I can highly recommend it! http://bit.ly/3F1gsJZ
#MTX #rheumedu #RheumTwitter #medtwitter
2 pivotal RCT studies lead to MTXs FDA approval in 1988
🔹Weinblatt: 24-week with 35 pts http://bit.ly/3ulhwU3
🔹Williams: 18-week with 189 pts http://bit.ly/3iAyzPv
2 smaller studies with positive results
🔹 http://bit.ly/3ulM7B2 & http://bit.ly/3B509KQ
8/🧵 #RheumEdu
Resistance:
🔹The outstanding results, by Dr Hoffmeister were only published as an abstract due to:
"the response to my abstract at the meeting was so negative that I did not want to spend the time submitting a manuscript only to have it rejected."